What is biomodal?
Multiomic sequencing technology for simultaneous genetic and epigenetic insight.
- Category
- Life sciences tools
- Headquarters
- Cambridge, United Kingdom
- Founded
- 2012
- Employees
- About 111 / 101-200 public profile range
- Total funding
- About $146M-$164M reported
- Status
- Private; valuation not disclosed
What is biomodal?
biomodal develops multiomic sequencing technology for simultaneous genetic and epigenetic insight.
biomodal, formerly Cambridge Epigenetix, develops sequencing chemistry and analytics that capture genetic and epigenetic information from the same DNA sample. Its duet multiomics products profile canonical bases plus methylation and hydroxymethylation signals for cancer, liquid biopsy, neurodegeneration, and research workflows.
The company has disclosed substantial late-stage financing, including an $88M Series D in 2021 that brought company-stated funding to $146M. It does not disclose product revenue, pricing, or valuation, so this profile uses public funding, product launches, and service-provider programs.
What does biomodal offer?
biomodal offers the product areas and capabilities below.
- duet multiomics solution evoC· Sequencing chemistry
- duet +modC· Sequencing chemistry
- 6-base genome workflows· Multiomics
- Low-input DNA workflows· Sample prep
- Certified Service Provider program· Channel
- Cancer and liquid biopsy research· Applications
How does biomodal make money?
biomodal's business model is based on enterprise or commercial offerings; public pricing is included only where disclosed.
biomodal makes money through life-sciences tools: kits, workflows, software/analytics, service-provider partnerships, and research or clinical-development customers. Public list pricing is not disclosed and purchases likely depend on kit volume, sample type, workflow, service provider, and support requirements.
Growth is driven by adoption of multiomic sequencing, liquid-biopsy research, certified service providers, and compatibility with existing sequencers. The company is not a SaaS vendor; procurement usually involves lab leadership, genomics scientists, bioinformatics, and purchasing teams.
Who leads biomodal?
biomodal is led by the public executives and founders listed below.
- Peter FromenChief Executive OfficerCEO listed on current team pageLeads commercialization and company strategy.
- Fiona StewartChief Financial OfficerExecutive teamFinance leader for private life-sciences scale-up.
- biomodal leadership teamExecutive leadershipCurrent team pageCompany lists a broader scientific, commercial, and operational leadership team.
How do you contact biomodal's leadership?
Use biomodal's official published aliases or contact forms; unverified personal emails are not listed as verified.
Use official contact routes; personal executive format not verifiedHow much funding has biomodal raised?
biomodal's public capital history is summarized from disclosed rounds, public filings, or acquisition records.
biomodal disclosed a $21M Series B led by GV in 2016, with support from Sequoia and other investors. In 2021, while still Cambridge Epigenetix, it announced an $88M Series D led by Temasek with participation from Third Point and existing investors including GV, New Science Ventures, Ahren, and Sequoia.
The 2021 announcement stated total funds raised to date of $146M. Some data providers later report about $164M across five rounds; valuation remains private and undisclosed.
How did biomodal get here?
biomodal's path is defined by the public milestones below.
- 2012Founded as Cambridge EpigenetixCompany began as a Cambridge life-sciences tools company.
- 2016Series BGV led a $21M Series B with Sequoia participation.
- 2021Nature Biotechnology publicationThe company published simultaneous genetic and epigenetic sequencing work.
- 2021Series DThe company raised $88M led by Temasek.
- 2023Rebrand to biomodalCambridge Epigenetix rebranded as biomodal.
- 2025CSP programbiomodal launched a certified service provider program for duet multiomics.
Who are biomodal's competitors?
biomodal competes with the companies listed below depending on buyer segment and use case.
- IlluminaSequencing platform leader with broad installed base.
- 10x GenomicsSingle-cell and spatial biology tools company.
- QIAGENSample-to-insight molecular biology and diagnostics tools vendor.
- PacBioLong-read sequencing platform company.
- Oxford NanoporeNanopore sequencing platform for direct nucleic-acid analysis.
biomodal — frequently asked questions
